跳至主要内容
临床试验/NCT06801899
NCT06801899招募中不适用

ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial

Insel Gruppe AG, University Hospital Bern18 个研究点 分布在 2 个国家目标入组 170 人开始时间: 2026年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
170
试验地点
18
主要终点
Overall survival (OS)

研究概览

简要总结

The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:

Does total pancreas removal improve survival without reducing quality of life compared to partial removal?

The only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.

详细描述

The pancreas is located in the upper abdomen and has 2 main functions: Production of digestive juices and of insulin, the latter being most important for blood sugar regulation and energy conservation. Certain types of cancer in the pancreatic head are very aggressive, but with complete surgical removal of the tumor and additional chemotherapy cure is possible. For tumor resection, the head of the pancreas as well as duodenum and part of the bile duct are removed. 3 new connections are built: the remaining pancreas, bile duct and stomach are connected to a loop of small intestine.

This operation takes around 6 hours and leads to complications in 20-30% of cases. A serious complication and unfortunately the most frequent is the leaking of the pancreas remnant, with outflow of the aggressive digestive juice into the surrounding tissue. Consequences may be severe bleeding and/or infections. Many studies show that affected patients have an increased risk of tumor recurrence and a reduced survival.

To avoid pancreatic leak, the entire pancreas can be removed. So far, removal of the whole pancreas has only been chosen in cases of very advanced cancer. After both, partial or total pancreas removal, patients need to substitute digestive enzymes. This can be done by capsules, which need to be taken with every meal. But while some patients after partial removal maintain sufficient function to produce insulin, all patients after total removal are diabetic and need insulin injections. In the past, blood sugar control in the absence of insulin production was difficult and accompanied by low quality of life (QoL). This has changed tremendously by the introduction of continuous glucose monitoring (sensors, which are attached to the arm) and automated insulin delivery systems (also known as "artificial pancreas"). This development renders total pancreas removal a reasonable alternative, with the advantage, that only 2 new connections are made: One between the bile duct and small intestine and one between the stomach and the small intestine.

Study question: Is removal of the whole pancreas in patients at high risk of a pancreatic leakage a preferable alternative to partial removal?

For this study, patients with cancer of the pancreatic head who are planned for surgery can be included. These patients will be randomly assigned to two groups:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and/or ampullary cancer (pancreaticobiliary type)
  • Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade "D" according to Schuh et al. (29): Estimation by CT scan, MRI, and/or Endoscopic Ultrasound
  • Written informed consent

排除标准

  • Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis
  • Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator
  • Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)
  • Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.

研究组 & 干预措施

Pancreaticoduodenectomy (PD)

Active Comparator

干预措施: Partial pancreaticoduodenectomy (PD) (Procedure)

Total pancreatectomy (TP)

Experimental

干预措施: Total pancreatectomy (TP) (Procedure)

结局指标

主要结局

Overall survival (OS)

时间窗: At 2 years

Number of participants who survived for 2 years after surgery.

次要结局

  • Quality of Life (QoL) Pancreatic Cancer(At 0.5 year, at 1 year, at 2 years)
  • Quality of Life (QoL) Diabetes(At 0.5 year, at 1 year, at 2 years)
  • Postoperative complications (discriminating minor and major complications)(Within 30 day of surgery)
  • Mortality(Within 30 days of surgery)
  • Length of hospital stay in days(Within 30 days of surgery)
  • Re-admission(Within 30 days of surgery)
  • Re-operation(Within 30 days of surgery)
  • Adjuvant Chemotherapy (ACT) completion(At 1 year)
  • Adjuvant Chemotherapy (ACT) initiation(At 1 year)
  • Disease-Free Survival (DFS)(At follow-up, up to 4.5 years)
  • Functional status(At 0.5 year, at 1 year, at 2 years)
  • Body Mass Index (BMI)(At 0.5 year, at 1 year, at 2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验